Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease.

Journal Article (Journal Article)

Etoposide, a semisynthetic derivative of podophyllotoxin, was evaluated concurrently in vitro against a human derived hormone-resistant cell line, PC-3, and in vivo in bidimensionally measurable hormone-resistant human prostatic cancer. In vitro, a dose-response relationship was observed, with 74% inhibition at 10 micrograms/ml (1 h incubation) and greater than 99% inhibition at 90 micrograms/ml, both in the range of clinically achievable concentrations. In vivo, 1 PR (5%, 95% confidence limits 0-12%) of 18+ months was observed in 20 adequately treated patients. The results confirm the limited role of etoposide in hormone-refractory disease and the need for new model systems for evaluation of potential chemotherapeutic compounds in this disease.

Full Text

Duke Authors

Cited Authors

  • Scher, HI; Sternberg, C; Heston, WD; Watson, RC; Niedzwiecki, D; Smart, T; Hollander, P; Yagoda, A

Published Date

  • 1986

Published In

Volume / Issue

  • 18 / 1

Start / End Page

  • 24 - 26

PubMed ID

  • 3757155

International Standard Serial Number (ISSN)

  • 0344-5704

Digital Object Identifier (DOI)

  • 10.1007/BF00253058


  • eng

Conference Location

  • Germany